iii blocking Mn uptake into the Golgi protected against GPP130 degradation, suggesting GPP130 may also play a role in cellular Mn homeostasis (Mukhopadhyay et al., 2010) . Here, we investigated the specific, sensitive, and temporal response of GPP130 to Mn in AF5 GABAergic neuronal cells, and whether GPP130 degradation occurs in brain cells in vivo in rats subchronically exposed to Mn. Results show that GPP130 degradation is specific to Mn in AF5 cells, and does not occur following exposure to cobalt, copper, iron, nickel, or zinc.
GPP130 degradation occurs without measurable increases in intracellular Mn levels and at
Mn exposures as low as 0.54 µM. Furthermore, GPP130 protein was detected in only ~15 -30 % of striatal and cortical brain cells in control animals, and Mn-exposed animals exhibited a significant reduction in both the number of GPP130-postive cells, and the overall cellular levels of GPP130 protein, demonstrating the in vivo relevance of this Mn-specific response within the primary target organ of Mn toxicity. These results may provide insight into important specific mechanism(s) of cellular Mn regulation and toxicity within the brain, including the selective susceptibility of cells to Mn cytotoxicity.
Introduction
Manganese (Mn) is a transition metal that serves as a cofactor for a number of enzymes, and is essential for many biological processes, including brain development (Keen, 1984; Prohaska, 1987) . At elevated exposures, however, Mn can accumulate widely throughout the brain and act as a neurotoxin (Reaney et SPCA1 is a Golgi transmembrane protein in the brain capable of transporting Mn into the Golgi lumen with high affinity (Sepulveda et. al., 2009 ). Studies by Leitch et al. (2011) showed that SPCA1 knock down in hepatocyte derived (WIF-B) cells led to an increase in Mn specific cell death, whereas over expression of SPCA1 in human embryonic kidney cells (HEK-293T) protected cells against Mn toxicity. Similarly, Mukhopadhyay et al. (2011) reported that increased activity of SPCA1 led to increased Mn transport into the Golgi and decreased Mn cytotoxicity in HeLa cells, while blocking Mn transport into or out of the Golgi increased cytotoxicity, suggesting that the Golgi may play an important role in Mn homeostasis and detoxificiation in HeLa cells.
Additionally, Mukhopadhyay et al. (2010) reported that elevated (500 µM) exposure and uptake of Mn into the Golgi of HeLa cells led to the lysosomal degradation of Golgi Phosphoprotein 4 (GPP130), and that blocking Mn uptake into the Golgi protected against GPP130 degradation, suggesting GPP130 may also play a role in cellular Mn homeostasis.
The cellular function(s) of GPP130, a cis-Golgi associated transmembrane protein, is not fully understood, but it has been shown to mediate the cellular trafficking of protein cargo from the endosome to the Golgi via the bypass pathway. By utilizing this bypass pathway, proteins and toxins are able to avoid lysosomal degradation and are able to exhibit their effects by trafficking to the Golgi (Mukhopadhyay et al., 2010) . Knockdown of GPP130 leads to increased cycling of endosomal proteins between the cell surface and endosomes (Linstedt et al., 1997; Natarajan and Linstedt, 2004) . However, the relationship between Mn and GPP130 within neuronal cells, and the extent that Mn, versus other divalent cations, specifically elicits GPP130 degradation within brain cells in vivo is not known.
The objectives of this study were to demonstrate the specific, sensitive, and temporal response of GPP130 to Mn exposure in AF5 GABAergic neuronal cells, and to determine the extent to which GPP130 degradation occurs in brain cells in vivo in rats subchronically exposed to Mn. Our results show that GPP130 degradation is specific to Mn in AF5 cells, and does not occur following exposure to cobalt, copper, iron, nickel, or zinc. GPP130 degradation occurs rapidly (<1 hr post Mn exposure) and at Mn exposures as low as 0.54 µM, which are nearly 100-times lower than previously reported exposures leading to GPP130 degradation (Mukhopadhyay et al., 2010; . Furthermore, GPP130 protein was detected in only ~15 -30 % of striatal and cortical brain cells in control animals, and Mn-exposed animals exhibited a significant reduction in both the number of GPP130-postive cells, and the overall cellular levels of GPP130 protein, demonstrating the in vivo relevance of this Mnspecific response within the predominant target organ of Mn toxicity. These results may provide insight into important specific mechanism(s) of cellular Mn regulation and toxicity within the brain.
Materials and Methods

Cell Culture
The immortalized mesencephalic-derived AF5 cell line was a generous gift provided The actual metal concentrations in control and exposure medium were determined using a Finnigan MAT Element high resolution inductively coupled plasma -mass spectrometer (ICP-MS), as described below. Following treatment, cells were harvested by trypsinization and collected for analysis by centrifugation at 10,000 x g for 10 minutes; cell pellets were frozen at -80°C until further analysis. Lysate protein concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL), following the manufacturers instructions.
Immunoblot Analysis
AF5 cell pellets were lysed in RIPA buffer and sonication, and lysates were adjusted to identical total protein concentrations following measurement of total lysate protein levels using the BCA assay. Cell lysate protein (20 µg per lane) and the molecular weight marker (10 µg) were separated by SDS-PAGE on a 4-12% Bis-Tris gel (Novex; Invitrogen Life Technologies, Gaithersburg, Md.) and transferred to a PVDF membrane. Membranes were blocked in 5% non-fat dry milk tris-buffered saline and Tween (PlusOne Tween 20; GE Healthcare Life Sciences, Pittsburgh, PA) (TBST) overnight at 4°C. Membranes were incubated with primary antibody (Anti-GOLPH4, ab28049; Abcam, Cambridge, UK) (1:1000) for 1 hour, washed in TBST, and then incubated with secondary antibody (bovine anti-rabbit IgG-HRP, sc-2370; Santa Cruz Biotech, Santa Cruz, CA) (1:1000) for 1 hour. The membranes were visualized using ECL Plus (GE Healthcare Life Sciences, Pittsburgh, PA) and imaged using a Typhoon Fluorescent Scanner. The protein bands were analyzed using ImageQuant.
Intracellular Mn Concentration Measurement
Cellular Mn levels were measured using trace metal clean methods as previously described (Crooks et. al 
Animals and Mn Treatment
Adult female Long Evans (Rattus Norvegicus) rats were dosed with either control vehicle (n=3) or 9.6 mg Mn/kg (n=3) by intraperitoneal (i.p.) injection, once a day, 3 days a week, for a duration of 4 weeks. A Mn stock solution of 49.6 mg/mL was prepared using MnCl 2 -hexahydrate diluted in Milli-Q water, and subsequently diluted to 6.7 mg/mL and filter sterilized for delivery to the animals. Manganese concentrations in the dosing solutions were routinely verified by atomic absorption spectrometry. This Mn exposure regimen was selected based on prior studies in our lab showing it was well-tolerated but produced subtle neurochemical and neuromotor deficits (Gwiazda et. al., 2007 ).
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Perfusion and Blood and Tissue Collection
Twenty-four hours after the final dose was administered, the rats were sacrificed by i.p. injection with 75 mg/kg pentobarbital, followed immediately by whole blood collected via cardiac puncture, and in situ brain fixation via upper body perfusion through the heart with ice cold 4% paraformaldehyde (PFA). The brain was removed and immediately immersed in 4% PFA and fixed for 12 hours at 4°C. The solution was changed to a 10% sucrose solution and fixed for 24 hours at 4°C, and then the solution was changed again to a 30% sucrose solution for 48 hours at 4°C. Whole brains were then embedded in freezing medium and stored at - 
Confocal Microscopy
Immunostained brain slices were analyzed using a Zeiss LSM 5 Pascal Laser Scanning Microscope. All images on each slide were taken with constant settings at either x20 or x63 magnification using the same detector gain and amplifier offset settings within each magnification for fluorescent image comparison. The x20 images were taken from two separate fields per brain region per brain slice, while the x63 images were taken from 10 separate fields per brain region per slice.
Image Analysis and Quantification
Brain slices per region per animal were qualitatively scored for protein fluorescence as previously described (Kern et. al 2010) . A total of six (x20 cortex) or one (x63 cortex and Fluorescence density in the Mn-treated animals was compared with that of control animals within each slide to determine Mn effects. Threshold limits were set by analyzing three fields/brain over three brain slices/animal and identifying the cells that were considered to be positive. From this, the Approximate Minimum Width, Approximate Maximum Width, and Intensity Above Local Background settings were adjusted and set to capture and identify all cells that were determined to be positive within a given field; these settings were 3 µm, 15 µm, and 80 gray/level, respectively.
Statistical Analysis
Treatment comparisons were made using analysis of variance (ANOVA) and Tukey's post hoc tests. P-Values of <0.05 were considered statistically significant. All analyses were conducted using JMP software (Version 9.0; SAS Institute).
Results
GPP130 degradation in AF5 cells is Mn-specific.
In order to provide insight into the cellular regulation of Mn and/or the mechanism of cellular Mn toxicity, we investigated whether GPP130 degradation in AF5 neuronal-like cells was Mn-specific, or if GPP130 degradation also occurred with other divalent metal treatments. Results show that Mn exposure (150 µM) led to >80% reduction in cellular GPP130 protein levels, while exposure to Ni, Zn, Co (all 150 µM), and Fe (300 µM) had no measurable effect (Figure 1) . Interestingly, treatment with 150 µM Cu led to a small (~17%) but statistically significant increase in GPP130 protein levels, compared to control. These results demonstrate that the effect of metal exposure on GPP130 degradation, at metal levels that do not cause measurable overt cytotoxicity (Crooks et al., 2007a) , is highly Mn-specific.
GPP130 degradation in AF5 cells is sensitive to unmeasureable changes in intracellular Mn concentration.
To elucidate the sensitivity of the GPP130 response to Mn over the transition from physiologic to supra-physiologic intracellular Mn levels, AF5 cells were treated with a range of physiologically relevant and sub-toxic Mn concentrations. Results show that significant cellular GPP130 degradation (~50% reduction) can be observed at the lowest Mn exposure level explored here (0.54 µM) (Figure 2a. ), even though total intracellular Mn concentrations did not measurably increase until Mn exposure levels in the medium reached 140 µM ( Figure   2b ). Note, however, there that there were trending but non-significant (p=~0.1) increases in intracellular Mn levels at the 5.3 and 27 µM exposure levels. This indicates that GPP130 degradation is highly sensitive to Mn exposure, occurring at exposure levels below those that produce measureable increases in intracellular Mn.
GPP130 degrades rapidly over time in parallel with a rapid increase, then decrease in intracellular Mn concentrations.
In order to evaluate the rapid temporality of the GPP130 response to Mn exposure, µM and 140 µM treatments (to ~40% and 25% of control, respectively), with small but significant increases (recovery) in cellular GPP130 levels by 24 hours (to ~55% and 45% of control, respectively) ( Figure 4A) . Notably, the apparent rate of GPP130 recovery after the cessation of Mn exposure was nearly identical in both the 5.4 µM and 140 µM treatment groups. In parallel, intracellular Mn levels increased significantly after 8 hours exposure to 140 µM Mn, which then rapidly and significantly declined after cessation of Mn exposure over the subsequent 16 hours; in contrast, intracellular Mn levels were not measurably increased after 8 hours exposure to 5 µM Mn, nor did levels measurably change after cessation of exposure ( Figure 4B ). These data indicate that recovery of cellular GPP130 levels following cessation of Mn exposure is incomplete and temporally much slower compared to the initial degradation response to Mn.
GPP130 degradation occurs in vivo in response to Mn and may be cell specific.
We explored whether sub-chronic Mn exposure in rats resulted in reductions in brain GPP130 protein levels in order to validate the relevance of our in vitro findings in AF5 neuronal-like cells in intact organisms. For this, rats were exposed to Mn for 4 weeks using an exposure regimen (9.6 mg/kg/d x 3 days/week x 4 weeks via i.p. injection) shown to produce subtle asymptomatic neurotoxic effects (Gwiazda et. al., 2005) . Results show that there was no significant difference in the total number of cells detected via Draq5 staining in either the cortex or dorsal striatum of control versus Mn treated animals (Table I) . However, there was a significant reduction in the percentage of cells that were identified as GPP130-positive in Mn-treated animals, with ~20 -30% of cells identified as GPP130-positive in the S1 dysgranular zone of the cortex of control animals compared to <10% in Mn-treated animals (p<0.001), based on Metamorph analysis of images at x20 and x63 magnification.
Similar differences between control and Mn-exposed animals occurred in the dorsal striatum (i.e., 10 -20% GPP130-positive cells in controls versus 4 -5% in Mn-treated animals, p<0.05) ( Table I ).
It is noteworthy that only ~20 -30% of Draq5-identified cells in the S1 dysgranular zone of the cortex and 10 -20% in the dorsal striatum of control animals were identified as GPP130 positive using the defined threshold criteria (see Materials and Methods) (Table I, We also evaluated whether dorsal striatal cells similarly responded to Mn exposure using the x63 images, since the striatum is a well-recognized target region for Mn neurotoxicity (Gwiazda et al., 2002) . Results show that GPP130 protein levels in striatal cells were decreased to ~50% of controls based on total fluorescence across all cells, and that Mn treatment reduced the number of cells identified as GPP130-positive to ~20% of controls (Table II) Table I ). Thus, the Mn effect on GPP130 protein levels in the dorsal striatum is very comparable to results in the cortex brain region (Figure 6b , Table I and   II) . It is noteworthy, however, that the GPP130 staining pattern in the striatum appeared different than in the cortex. In the striatum, GPP130 staining appeared primarily on the surface of the cells, and was typically localized to cell processes ( The very low Mn exposure levels that elicited the degradation of GPP130 protein are noteworthy because they span the physiologic to supra-physiologic range. The lowest level of Mn exposure explored here that caused a significant reduction in cellular GPP130 protein levels, 0.54 µM Mn, was only ~6-fold higher than background Mn levels in the culture medium (0.09 µM Mn), and represents a relative increase that is well within the range of differences in blood Mn concentrations in humans. For instance, normal adult blood Mn levels range from ~7 -14 ng/mL (i.e., 0.14 -0.28 µM Mn), though levels in women during late term pregnancy and in neonates range from 40 -70 ng/mL (i.e., 0.8 -1. Mn levels were not reported in that study. Collectively, these Mn exposure levels and resultant intracellular Mn concentrations were ~5 to 1000 fold higher than exposure levels that generated a GPP130 degradation response in the present study, further underscoring the highly sensitive and specific nature of the GPP130 degradation response to Mn.
Finally, brain Mn levels were not determined in the animal studies reported here because brains were PFA-perfused in situ, thereby potentially altering inherent brain Mn levels. However, previous studies in our lab showed that a comparable Mn exposure regimen (i.e., 9.6 mg Mn/kg/day i.p. x 3 doses/wk x 5 wks) produced brain Mn levels of ~1. 
